174 related articles for article (PubMed ID: 2123914)
1. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.
García-Pagán JC; Feu F; Navasa M; Bru C; Ruiz del Arbol L; Bosch J; Rodés J
J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914
[TBL] [Abstract][Full Text] [Related]
2. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
[TBL] [Abstract][Full Text] [Related]
3. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.
Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC
J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395
[TBL] [Abstract][Full Text] [Related]
4. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension.
Piscaglia F; Donati G; Gaiani S; Gramantieri L; Leoni S; Mancini M; Bolondi L
Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844
[TBL] [Abstract][Full Text] [Related]
5. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.
Navasa M; Chesta J; Bosch J; Rodés J
Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
Garcia-Pagán JC; Navasa M; Bosch J; Bru C; Pizcueta P; Rodés J
Hepatology; 1990 Feb; 11(2):230-8. PubMed ID: 2307401
[TBL] [Abstract][Full Text] [Related]
7. Effect and mechanism of action of isosorbide-5-mononitrate.
Hayes PC; Westaby D; Williams R
Gut; 1988 Jun; 29(6):752-5. PubMed ID: 3384359
[TBL] [Abstract][Full Text] [Related]
8. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
García-Pagán JC; Feu F; Bosch J; Rodés J
Ann Intern Med; 1991 May; 114(10):869-73. PubMed ID: 2014947
[TBL] [Abstract][Full Text] [Related]
9. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
10. Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension.
Mols P; Hallemans R; Melot C; Lejeune P; Naeije R
J Hepatol; 1989 May; 8(3):316-24. PubMed ID: 2732445
[TBL] [Abstract][Full Text] [Related]
11. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis.
Tsai YT; Lee FY; Lin HC; Chang TT; Lay CS; Wang SS; Kong CW; Lee SD; Lo KJ
Hepatology; 1989 Sep; 10(3):283-7. PubMed ID: 2759546
[TBL] [Abstract][Full Text] [Related]
12. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
[TBL] [Abstract][Full Text] [Related]
13. [Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events].
Castaño G; Viudez P; Sookoian S; Carlevaro O; Riccitelli M; Frider B
Gastroenterol Hepatol; 2000; 23(6):275-81. PubMed ID: 15324622
[TBL] [Abstract][Full Text] [Related]
14. Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.
Jones AL; Bangash IH; Walker J; Simpson KJ; Finlayson ND; Hayes PC
Gut; 1995 Jan; 36(1):104-9. PubMed ID: 7890211
[TBL] [Abstract][Full Text] [Related]
15. Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver.
Cervinka J; Kordac V; Kalab M
J Int Med Res; 1989; 17(6):560-4. PubMed ID: 2628133
[TBL] [Abstract][Full Text] [Related]
16. Clinical vs haemodynamic response to drugs in portal hypertension.
McCormick PA; Patch D; Greenslade L; Chin J; McIntyre N; Burroughs AK
J Hepatol; 1998 Jun; 28(6):1015-9. PubMed ID: 9672178
[TBL] [Abstract][Full Text] [Related]
17. Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function.
Ikegami M; Toyonaga A; Tanikawa K
Am J Gastroenterol; 1992 Sep; 87(9):1160-4. PubMed ID: 1519573
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.
Merkel C; Sacerdoti D; Bolognesi M; Enzo E; Marin R; Bombonato G; Angeli P; Gatta A
Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449
[TBL] [Abstract][Full Text] [Related]
19. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis.
Merkel C; Finucci G; Zuin R; Bazzerla G; Bolognesi M; Sacerdoti D; Gatta A
J Hepatol; 1987 Apr; 4(2):174-80. PubMed ID: 3584925
[TBL] [Abstract][Full Text] [Related]
20. Duplex Doppler ultrasonography allows a multiorgan noninvasive approach to splanchnic pharmacodynamics in patients with cirrhosis.
Bolognesi M; Sacerdoti D; Merkel C; Caregaro L; Bellon S; Gatta A
Bildgebung; 1995 Jun; 62(2):138-43. PubMed ID: 7663138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
